AR123935A1 - COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g - Google Patents
COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d gInfo
- Publication number
- AR123935A1 AR123935A1 ARP210102983A ARP210102983A AR123935A1 AR 123935 A1 AR123935 A1 AR 123935A1 AR P210102983 A ARP210102983 A AR P210102983A AR P210102983 A ARP210102983 A AR P210102983A AR 123935 A1 AR123935 A1 AR 123935A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- antibody
- target
- trgdc
- trdv2
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000036039 immunity Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 10
- 210000004027 cell Anatomy 0.000 abstract 5
- 108091008874 T cell receptors Proteins 0.000 abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 abstract 3
- 102000001398 Granzyme Human genes 0.000 abstract 3
- 108060005986 Granzyme Proteins 0.000 abstract 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 abstract 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 3
- 101000649129 Homo sapiens T cell receptor delta variable 2 Proteins 0.000 abstract 3
- 101000680681 Homo sapiens T cell receptor gamma variable 9 Proteins 0.000 abstract 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 3
- 102100027948 T cell receptor delta variable 2 Human genes 0.000 abstract 3
- 102100022393 T cell receptor gamma variable 9 Human genes 0.000 abstract 3
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente descripción, en ciertos aspectos, se proporcionan anticuerpos que se unen al receptor de células T (TCR) Vg9 (TRGV9), TCR Vd2 (TRDV2), o la región constante g / d del TCR (TRGDC), así como células recombinantes que contienen los vectores y composiciones que comprenden los anticuerpos. También se proporcionan métodos para preparar y usar los anticuerpos. Reivindicación 24: Una secuencia de ácido nucleico que codifica el anticuerpo de una cualquiera de las reivindicaciones 1 a 23. Reivindicación 25: Un vector que comprende la secuencia de ácido nucleico de la reivindicación 24. Reivindicación 26: Una célula huésped que comprende el vector de la reivindicación 25. Reivindicación 29: Una composición farmacéutica que comprende el anticuerpo de una cualquiera de las reivindicaciones 1 a 23, y un portador farmacéuticamente aceptable. Reivindicación 30: Un método para producir la composición farmacéutica de la reivindicación 28, que comprende combinar el anticuerpo con un portador farmacéuticamente aceptable para obtener la composición farmacéutica. Reivindicación 31: Un método para dirigir una célula T gd a una célula diana, el método comprende poner en contacto la célula T gd con el anticuerpo multiespecífico de la reivindicación 23, en donde la célula diana expresa la segunda diana, y en donde el contacto hace que la célula T gd se dirija a la célula diana. Reivindicación 37: Un método para activar una célula T, en donde: (a) la célula T expresa TRGV9, y el método comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 1, 4 a 12, ó 21 a 23; en donde opcionalmente el contacto resulta en un aumento en la expresión de CD69, CD25, y/o granzima B, en comparación con una célula T de control que expresa TRGV9; (b) la célula T expresa TRDV2, y el método comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 2, 4 a 8, 13 a 16, ó 21 a 23; en donde opcionalmente el contacto resulta en un aumento en la expresión de CD69, CD25, y/o granzima B, en comparación con una célula T de control que expresa TRDV2; o (c) la célula T expresa TRGDC, y el método comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 3 a 8, ó 17 a 23; en donde opcionalmente el contacto resulta en un aumento en la expresión de CD69, CD25, y/o granzima B, en comparación con una célula T de control que expresa TRGDC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106703P | 2020-10-28 | 2020-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123935A1 true AR123935A1 (es) | 2023-01-25 |
Family
ID=81256812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102983A AR123935A1 (es) | 2020-10-28 | 2021-10-27 | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220125947A1 (es) |
| EP (1) | EP4237003A1 (es) |
| JP (1) | JP2023548109A (es) |
| KR (1) | KR20230093503A (es) |
| CN (1) | CN116390950A (es) |
| AR (1) | AR123935A1 (es) |
| AU (1) | AU2021372463A1 (es) |
| CA (1) | CA3199767A1 (es) |
| TW (1) | TW202233674A (es) |
| UY (1) | UY39488A (es) |
| WO (1) | WO2022093888A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20210548A (es) | 2019-05-08 | 2022-02-11 | Janssen Biotech Inc | Materiales y métodos para modular la inmunidad mediada por células t |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2595385C2 (ru) * | 2010-08-05 | 2016-08-27 | Анаптисбайо, Инк. | Антитела, направленные против il-17 |
| US10501540B2 (en) * | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| SI3303394T1 (sl) * | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
-
2021
- 2021-10-27 AR ARP210102983A patent/AR123935A1/es unknown
- 2021-10-27 EP EP21887391.7A patent/EP4237003A1/en active Pending
- 2021-10-27 AU AU2021372463A patent/AU2021372463A1/en active Pending
- 2021-10-27 US US17/512,195 patent/US20220125947A1/en active Pending
- 2021-10-27 CN CN202180074296.XA patent/CN116390950A/zh active Pending
- 2021-10-27 WO PCT/US2021/056744 patent/WO2022093888A1/en active Application Filing
- 2021-10-27 KR KR1020237017991A patent/KR20230093503A/ko unknown
- 2021-10-27 JP JP2023525958A patent/JP2023548109A/ja active Pending
- 2021-10-27 UY UY0001039488A patent/UY39488A/es unknown
- 2021-10-27 CA CA3199767A patent/CA3199767A1/en active Pending
- 2021-10-27 TW TW110139845A patent/TW202233674A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022093888A1 (en) | 2022-05-05 |
| JP2023548109A (ja) | 2023-11-15 |
| UY39488A (es) | 2022-04-29 |
| CN116390950A (zh) | 2023-07-04 |
| AU2021372463A1 (en) | 2023-06-22 |
| EP4237003A1 (en) | 2023-09-06 |
| US20220125947A1 (en) | 2022-04-28 |
| CA3199767A1 (en) | 2022-05-05 |
| TW202233674A (zh) | 2022-09-01 |
| KR20230093503A (ko) | 2023-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069776A1 (es) | Anticuerpos bivalentes biespecificos | |
| AR126987A2 (es) | Inmunoconjugados | |
| AR118118A2 (es) | Anticuerpos bivalentes biespecíficos | |
| HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| PE20211498A1 (es) | Anticuerpos dirigidos contra il-11 | |
| PE20211500A1 (es) | Anticuerpos dirigidos contra il-11ra | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| BRPI0812091A2 (pt) | Método para fabricar uma proteína policlonal recombinante | |
| BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
| AR074124A1 (es) | Composiciones y metodos para inhibir la expresion de genes del factor vii | |
| AR085404A1 (es) | Proteinas de union a antigeno | |
| BR112012026766A2 (pt) | métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica. | |
| CL2008002349A1 (es) | Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. | |
| BR112016007547A2 (pt) | ?vetor de expressão bicistrônico para expressão de anticorpos e método para a produção de anticorpos usando o mesmo? | |
| BR112014006176A8 (pt) | Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada | |
| BR112018017194A2 (pt) | vetor, célula cancerosa ou célula imune, e, medicamento. | |
| CL2020003343A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de los mismos para la introducción dirigida de material genético a células humanas (divisional de la solicitud 201903842) | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| CO2022015202A2 (es) | Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos | |
| AR123935A1 (es) | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g | |
| AR103172A1 (es) | Reducción selectiva de residuos de cisteina en anticuerpos il-17 | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| BR112018072434A2 (pt) | modulação do metabolismo lipídico para a produção de proteína | |
| MX2021012003A (es) | Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |